spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Pancreatic Adenocarcinoma 

 HSMN NewsFeed - 9 Jun 2023
Astellas Submits New Drug Application for Zolbetuximab in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Oct 2020
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jan 2017
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 18 Oct 2016
Shire Granted EU Marketing Authorization of Onivyde(R), in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Mar 2016
Merrimack Announces Inclusion of ONIVYDE(R) (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2015
Merck KGaA, Darmstadt, Germany, Decides Not to Pursue Evofosfamide Further in Soft Tissue Sarcoma and Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2014
Novocure Enrolls First Patient in Pilot Clinical Trial of NovoTTF(TM) Therapy Plus Gemcitabine for First-line Treatment of Advanced Pancreatic Adenocarcinoma
Devices Oncology
 HSMN NewsFeed - 6 Sep 2013
U.S. Food and Drug Administration Approves ABRAXANE(R) in Combination with Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Jul 2012
Journal of the American College of Surgeons Publishes Study on Using the NanoKnife(R) System to Treat Liver Tumors Adjacent to Blood Vessels
Devices Surgery Oncology
 HSMN NewsFeed - 3 Feb 2012
Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2011
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Dec 2010
SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Oct 2009
ASTRO Presentations Highlight Role of TomoTherapy(R) Technology in Combined Modality Approach to Treating Cancer
Devices Oncology
 HSMN NewsFeed - 25 Jun 2009
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2009
Sutent Significantly Increases Progression Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors, Study Stopped Early
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Nov 2007
NCCN Updates Pancreatic Adenocarcinoma Guidelines
Oncology
 HSMN NewsFeed - 26 Feb 2007
Threshold Pharmaceuticals Announces That a Phase 3 Clinical Trial of Glufosfamide for Treatment of Pancreatic Cancer Did Not Meet Its Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2006
Long-Term Results from TNFerade(TM) Pancreatic Cancer Study and Updated Survival Results from TNFerade(TM) Esophageal Cancer Study Both Reported at Digestive Disease Week
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
Pancreatic Adenocarcinoma
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.